GEMFIBROZIL IN THE TREATMENT OF LIPID DIS BOLISM

The study was made of gemfibrozil tolerance and effectivity against at herosclerosis and in correction of lipid metabolism in 20 patients wit h hyperlipidemia. (11 males and 9 females, a mean age 514 +/- 3.1 year s). The assessment of the treatment efficacy was performed clinically, biochemically, using bicycle ergometry exercise. Eight weeks of gemfi brozil treatment in a dose 12-1.8 g/day produced a hypolipidemic effec t in 90 % of the patients which were mostly of IIb and IV genotypes. T he highest efficacy was reported in lowering triglycerides, VLDL chole sterol. In less extent the drug reduced LDL cholesterol. Some of the p atients became hypolipidemic by HDL cholesterol. It is concluded that in hyperlipidemic patients gemfibrozil improves the running of atheros clerosis without the effect on angina pectoris.